Skip to main content

#151050

Anti-ERCC1 [ERCC1 3H11]

Cat. #151050

Anti-ERCC1 [ERCC1 3H11]

Cat. #: 151050

Sub-type: Primary antibody

Unit size: 100 ug

Availability: 3-4 weeks

Target: ERCC1

Class: Monoclonal

Application: IF ; IP ; WB

Reactivity: Human

Host: Mouse

£300.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Julian Gannon

Institute: Cancer Research UK, London Research Institute: Lincoln's Inn Fields

Tool Details
Target Details
Applications
Handling
References

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

  • Name: Anti-ERCC1 [ERCC1 3H11]
  • Alternate name: Cyclin-Dependent Kinase 1; Cell Division Cycle 2, G1 To S And G2 To M; Cell Division Control Protein 2 Homolog; Cell Division Protein Kinase 1; P34 Protein Kinase; P34CDC2; CDC28A; CDC2; Cell Cycle Controller CDC2; CDKN1
  • Research fields: Cancer;Genetics
  • Clone: ERCC1 3H11
  • Tool sub type: Primary antibody
  • Class: Monoclonal
  • Conjugation: Unconjugated
  • Molecular weight: 33-36
  • Strain: Balb/c
  • Reactivity: Human
  • Host: Mouse
  • Application: IF ; IP ; WB
  • Description: Nucleotide excision repair (NER) is a DNA repair pathway that removes lesions induced by a variety of agents such as UV irradiation. ERCC1 binds to XPF to form the heterodimer ERCC1-XPF, which is a DNA endonuclease that is essential for the dual incision step of NER (cleaves 5' of the DNA lesion). Some publications report that ERCC1 is elevated in cisplatin-resistant cells.
  • Immunogen: Full length HIS-tagged recombinant human ERCC1
  • Isotype: IgG2a
  • Myeloma used: Sp2/0-Ag14
  • Recommended controls: A431 cells or HeLa

Target Details

  • Target: ERCC1
  • Molecular weight: 33-36
  • Tissue cell line specificity: A431 cells or HeLa
  • Target background: Nucleotide excision repair (NER) is a DNA repair pathway that removes lesions induced by a variety of agents such as UV irradiation. ERCC1 binds to XPF to form the heterodimer ERCC1-XPF, which is a DNA endonuclease that is essential for the dual incision step of NER (cleaves 5' of the DNA lesion). Some publications report that ERCC1 is elevated in cisplatin-resistant cells.

Applications

  • Application: IF ; IP ; WB

Handling

  • Format: Liquid
  • Concentration: 1 mg/ml
  • Unit size: 100 ug
  • Storage buffer: PBS with 0.02% azide
  • Storage conditions: -15° C to -25° C
  • Shipping conditions: Dry ice

References

  • HCMV-infected cells maintain efficient nucleotide excision repair of the viral genome while abrogating repair of the host genome.
  • O'Dowd et al. 2012. PLoS Pathog. 8(11):e1003038. PMID: 23209410.
  • Bhagwat et al. 2009. Cancer Res. 69(17):6831-8. PMID: 19723666.
  • Immunodetection of DNA repair endonuclease ERCC1-XPF in human tissue.
  • Biggerstaff et al. 1993. EMBO J. 12(9):3685-92. PMID: 8253090.
  • Co-correction of the ERCC1, ERCC4 and xeroderma pigmentosum group F DNA repair defects in vitro.

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.